Alprostadil Injectable Drug Recalled for Manufacturing Quality Control Deviations
Olympia Compounding Pharmacy is recalling 460 vials of Alprostadil 80 mcg/mL due to manufacturing quality control deviations related to improper investigation of environmental and personnel monitoring excursions prior to October 2021.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall based on manufacturing quality control deviations. No illnesses, injuries, or deaths have been reported. The recall is precautionary in nature, based on procedural failures in manufacturing monitoring rather than direct evidence of product harm.
Plain-English summary
Olympia Compounding Pharmacy is recalling 460 vials of PGE-2 (Alprostadil 80 mcg/mL) nationwide due to manufacturing quality control deviations. The drug is a prescription injectable medication.
The recall was issued because, prior to October 1, 2021, environmental and personnel monitoring excursions exceeded the established Out of Action Limit (OOAL) but were not properly investigated by the manufacturer. This represents a deviation from Current Good Manufacturing Practice (CGMP) requirements.
The affected product is Lot F48102 with a Beyond Use Date of June 2, 2022, distributed nationwide in the United States.
Patients should speak with their healthcare provider or pharmacist if they have questions about this medication. Healthcare providers and pharmacies should stop distribution of affected vials and arrange return to the manufacturer.
The recalled product
- Product
- PGE-2, Alprostadil 80 mcg/mL, 10ml Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0029-10.
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable / Prescription
- Hazard
- cgmp-deviation
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: F48102 BUD: 6/2/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27